In up to 50% of HCCs, the mammalian target of rapamycin (mTOR) signaling are aberrantly hyperactivated to drive tumor progression by underwriting biosynthetic programs and promoting proliferation 3-5, which is associated with a poor prognosis, poor differentiation and earlier recurrence 5. The gene discussed is MTOR; the disease is neoplasm.